Published in Am J Kidney Dis on May 07, 2015
Optimal management of bone mineral disorders in chronic kidney disease and end stage renal disease. Curr Opin Nephrol Hypertens (2016) 0.75
High-Iron Consumption Impairs Growth and Causes Copper-Deficiency Anemia in Weanling Sprague-Dawley Rats. PLoS One (2016) 0.75
A Review of Phosphate Binders in Chronic Kidney Disease: Incremental Progress or Just Higher Costs? Drugs (2017) 0.75
Iron-based phosphate binders: a paradigm shift in the treatment of hyperphosphatemic anemic CKD patients? J Nephrol (2017) 0.75
K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis (2003) 16.18
Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol (2004) 11.23
Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int (2002) 9.29
The dialysis encephalopathy syndrome. Possible aluminum intoxication. N Engl J Med (1976) 5.10
Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol (2005) 4.44
Progressive accumulation of lanthanum in the liver of normal and uremic rats. Kidney Int (2005) 2.24
A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am J Kidney Dis (1999) 2.07
Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study). Kidney Int (2004) 2.01
Long-term effects of sevelamer hydrochloride on the calcium x phosphate product and lipid profile of haemodialysis patients. Nephrol Dial Transplant (1999) 1.77
An open-label, crossover study of a new phosphate-binding agent in haemodialysis patients: ferric citrate. Nephrol Dial Transplant (2002) 1.70
Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials. Am J Kidney Dis (2009) 1.31
Long-term efficacy and safety profile of lanthanum carbonate: results for up to 6 years of treatment. Nephron Clin Pract (2008) 1.29
Ferric citrate controls phosphorus and delivers iron in patients on dialysis. J Am Soc Nephrol (2014) 1.27
The safety and tolerability of ferric citrate as a phosphate binder in dialysis patients. Nephron Clin Pract (2012) 1.20
The DOPPS practice monitor for U.S. dialysis care: update on trends in anemia management 2 years into the bundle. Am J Kidney Dis (2013) 1.12
Dose-response and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: a short-term randomized trial. Am J Kidney Dis (2013) 1.10
Influence of dietary constituents on intestinal absorption of aluminum. Kidney Int (1989) 1.09
Hypercalcaemic osteomalacia due to aluminium toxicity. Lancet (1982) 1.08
Citrate: a major factor in the toxicity of orally administered aluminum compounds. Kidney Int (1989) 1.02
Association of malnutrition-inflammation complex and responsiveness to erythropoiesis-stimulating agents in long-term hemodialysis patients. Nephrol Dial Transplant (2012) 1.02
A randomized trial of JTT-751 versus sevelamer hydrochloride in patients on hemodialysis. Nephrol Dial Transplant (2013) 1.01
Ferric Citrate Reduces Intravenous Iron and Erythropoiesis-Stimulating Agent Use in ESRD. J Am Soc Nephrol (2015) 0.98
Rationale and study design of a three-period, 58-week trial of ferric citrate as a phosphate binder in patients with ESRD on dialysis. Hemodial Int (2012) 0.98
Influence of calcium acetate or calcium citrate on intestinal aluminum absorption. Kidney Int (1990) 0.96
Bile acid binding to sevelamer HCl. Kidney Int (2002) 0.96
Microcytic anemia in dialysis patients: reversible marker of aluminum toxicity. Am J Kidney Dis (1987) 0.90
Phosphorus binding with ferric citrate is associated with fewer hospitalizations and reduced hospitalization costs. Expert Rev Pharmacoecon Outcomes Res (2014) 0.87
Dialysate aluminium concentration and renal bone disease. Kidney Int (1982) 0.83
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med (2001) 17.24
Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial. Am J Kidney Dis (2011) 3.81
Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. J Am Soc Nephrol (2005) 2.25
Pyridorin in type 2 diabetic nephropathy. J Am Soc Nephrol (2011) 1.79
Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy. J Am Soc Nephrol (2011) 1.66
Severe lupus nephritis: racial differences in presentation and outcome. J Am Soc Nephrol (2006) 1.61
Establishment of the 1st World Health Organization International Standard for Plasmodium falciparum DNA for nucleic acid amplification technique (NAT)-based assays. Malar J (2008) 1.52
Value of a complete or partial remission in severe lupus nephritis. Clin J Am Soc Nephrol (2007) 1.39
Ferric citrate controls phosphorus and delivers iron in patients on dialysis. J Am Soc Nephrol (2014) 1.27
The safety and tolerability of ferric citrate as a phosphate binder in dialysis patients. Nephron Clin Pract (2012) 1.20
A World Health Organization International Standard for hepatitis A virus RNA nucleic acid amplification technology assays. Vox Sang (2005) 1.10
Dose-response and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: a short-term randomized trial. Am J Kidney Dis (2013) 1.10
The prognosis and pathogenesis of severe lupus glomerulonephritis. Nephrol Dial Transplant (2007) 1.05
Effects of sulodexide in patients with type 2 diabetes and persistent albuminuria. Nephrol Dial Transplant (2007) 1.01
Rationale and study design of a three-period, 58-week trial of ferric citrate as a phosphate binder in patients with ESRD on dialysis. Hemodial Int (2012) 0.98
Ferric Citrate Reduces Intravenous Iron and Erythropoiesis-Stimulating Agent Use in ESRD. J Am Soc Nephrol (2015) 0.98
The advanced glycation end product N(epsilon)-carboxymethyllysine is not a predictor of cardiovascular events and renal outcomes in patients with type 2 diabetic kidney disease and hypertension. Am J Kidney Dis (2006) 0.97
Establishment of the 1st World Health Organization international standards for human papillomavirus type 16 DNA and type 18 DNA. Int J Cancer (2010) 0.96
Rationale for and study design of the sulodexide trials in Type 2 diabetic, hypertensive patients with microalbuminuria or overt nephropathy. Diabet Med (2007) 0.95
Collaborative study to calibrate hepatitis C virus genotypes 2-6 against the HCV International Standard, 96/790 (genotype 1). Vox Sang (2003) 0.95
Collaborative study to establish a World Health Organization International genotype panel for parvovirus B19 DNA nucleic acid amplification technology (NAT)-based assays. Vox Sang (2011) 0.91
The natural history of maternal immunization against foetal platelet alloantigens. Transfus Med (2004) 0.91
Phosphorus binding with ferric citrate is associated with fewer hospitalizations and reduced hospitalization costs. Expert Rev Pharmacoecon Outcomes Res (2014) 0.87
Severe lupus nephritis: the predictive value of a ≥ 50% reduction in proteinuria at 6 months. Nephrol Dial Transplant (2013) 0.86
A collaborative study to establish the 1st WHO International Standard for human cytomegalovirus for nucleic acid amplification technology. Biologicals (2016) 0.86
Clinically unrecognized Q-wave myocardial infarction in patients with diabetes mellitus, systemic hypertension, and nephropathy. Am J Cardiol (2004) 0.86
Impact of irbesartan, blood pressure control, and proteinuria on renal outcomes in the Irbesartan Diabetic Nephropathy Trial. Kidney Int Suppl (2004) 0.85
Ferric Citrate, an Iron-Based Phosphate Binder, Reduces Health Care Costs in Patients on Dialysis Based on Randomized Clinical Trial Data. Drugs R D (2015) 0.83
C-reactive protein as a predictor of total arteriosclerotic outcomes in type 2 diabetic nephropathy. Kidney Int (2005) 0.83
Serum levels of the advanced glycation end products Nepsilon-carboxymethyllysine and pentosidine are not influenced by treatment with the angiotensin receptor II type 1 blocker irbesartan in patients with type 2 diabetic nephropathy and hypertension. Nephron Clin Pract (2008) 0.83
Effect of Lisinopril on the progression of renal insufficiency in mild proteinuric non-diabetic nephropathies. Nephrol Dial Transplant (2001) 0.83
A clinical trial in type 2 diabetic nephropathy. Am J Kidney Dis (2001) 0.80
The cost-effectiveness of irbesartan in the treatment of hypertensive patients with type 2 diabetic nephropathy. Clin Ther (2003) 0.80
Total plasma homocysteine and arteriosclerotic outcomes in type 2 diabetes with nephropathy. J Am Soc Nephrol (2005) 0.80
Residual proteinuria and eGFR predict progression of renal impairment within 2 years in type 2 diabetic patients with nephropathy who are receiving optimal treatment with angiotensin receptor blockers. Nephrology (Carlton) (2013) 0.80
A collaborative study to establish the 1st WHO International Standard for Epstein-Barr virus for nucleic acid amplification techniques. Biologicals (2016) 0.80
Complete remission in severe lupus nephritis: assessing the rate of loss in proteinuria. Nephrol Dial Transplant (2011) 0.79
Efficacy and tolerability of pale sulfonated shale oil cream 4% in the treatment of mild to moderate atopic eczema in children: a multicentre, randomized vehicle-controlled trial. J Eur Acad Dermatol Venereol (2010) 0.79
Comparison of Prescribed and Measured Dialysate Sodium: A Quality Improvement Project. Am J Kidney Dis (2016) 0.79
World Health Organization collaborative study to calibrate the 3rd International Standard for Hepatitis C virus RNA nucleic acid amplification technology (NAT)-based assays. Vox Sang (2010) 0.78
Proteinuria in type 2 diabetic patients with renal impairment: the changing face of diabetic nephropathy. Nephron Clin Pract (2011) 0.77
Subcutaneous low-dose epoetin beta for the avoidance of transfusion in patients scheduled for elective surgery not eligible for autologous blood donation. Eur Surg Res (2002) 0.77
Managing hyperphosphatemia in patients with chronic kidney disease on dialysis with ferric citrate: latest evidence and clinical usefulness. Ther Adv Chronic Dis (2015) 0.75
Tolerability and efficacy of multidose epoetin beta (Reco-Pen) for subcutaneous administration in patients with anemia due to renal failure. Kidney Blood Press Res (2003) 0.75
The Impact of Baseline Serum Creatinine on Complete Remission Rate and Long-Term Outcome in Patients with Severe Lupus Nephritis. Nephron Extra (2016) 0.75
Dialysate Potassium, Serum Potassium, Mortality, and Arrhythmia Events in Hemodialysis: Results From the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis (2016) 0.75
Incidence and Risk Factors for Hepatitis C Virus Infection among Illicit Drug Users in Italy. J Urban Health (2017) 0.75
Proteinuria as a predictor of total plasma homocysteine levels in type 2 diabetic nephropathy. Diabetes Care (2002) 0.75
International collaborative study on the 3rd WHO International Standard for hepatitis B surface antigen. J Clin Virol (2016) 0.75
Collaborative study to establish World Health Organization international reference reagents for dengue virus Types 1 to 4 RNA for use in nucleic acid testing. Transfusion (2017) 0.75
A collaborative study to establish the 3rd WHO International Standard for hepatitis B virus for nucleic acid amplification techniques. Biologicals (2017) 0.75
[Is the serum concentration of pentosidine a predictor of cardiovascular events in patients with type 2 diabetes and kidney disease?]. Dtsch Med Wochenschr (2007) 0.75